Prabhavathi Fernandes, Ph.D., Founder, President and Chief Executive Officer
Dr. Prabhavathi Fernandes has been President and Chief Executive Officer of Cempra Pharmaceuticals since its inception in January 2006. She was previously President and Chief Executive Officer of DarPharma, Ricerca Biosciences and Small Molecule Therapeutics. Prior to this, Dr. Fernandes held leadership positions at pharmaceutical corporations having worked at Bristol-Myers Squibb, Pharmaceutical Research Institute, Abbott Laboratories and The Squibb Institute for Medical Research. During these years she was directly involved in the development of antibiotics, four of which have been approved and one, Clarithromycin, achieving sales over a billion dollars. Dr. Fernandes has served on the U.S. Congressional Panel for Assessment of Impact of Antibiotic Resistant Bacteria and on the American Society for Microbiology Advisory Panel for Antibiotic Resistance. She serves on the editorial board of six journals, is a member of the Product Development working group for Biodefense for the NIAID, is an Advisory Board Member of Optimer Pharmaceuticals, Inc. and has written numerous publications and books. She was awarded a post-doctoral fellowship to Fox Chase Cancer Center from the National Institutes of Health and received her Ph.D. in Microbiology from Thomas Jefferson University.
Mark W. Hahn, Executive Vice President and Chief Financial Officer
Mr. Hahn has over 25 years of experience as a senior financial executive in biotechnology and high technology companies. he has conducted over $500 million in financial transactions for both public and private companies. Prior to joining Cempra, Mark was CFO of Athenix Corp., a leading agricultural biotechnology company where he led the company in its $400 million merger with Bayer CropScience. He previously was the CFO of several rapidly growing technology companies including BuildLinks, Inc. and Charles & Colvard, Ltd., where he led the growth of the firm from three to 75 employees and spearheaded that company's IPO. Mark began his career with Ernst & Young. Mr. Hahn holds a Bachelor of Business Administration degree in Accouning and Finance from the University of Wisconsin-Milwaukee and is a Certified Public Accountant in the State of Maryland.
Carl T. Foster, Executive Vice President, Business Development
Carl T. Foster is the Executive Vice President, Business Development for Cempra Pharmaceuticals. Prior to joining Cempra, he was CEO of Jurilab, a European-based genomics company. Carl has also held Vice President-level positions with Nanogen, King Pharmaceuticals, Oxford GlycoSciences and Praecis Pharmaceuticals and as General Manager of Intracel BV, a Netherlands-based immunology company. Prior to that he was with Merck, Inc. and Astra Merck where he had increasing levels of responsibilities in sales, marketing, product development, and business development. Mr. Foster has served as an advisor to pharmaceutical and biotechnology companies as a consultant and as a Managing Director with Ferghana Partners, Inc., an international investment banking group in New York. Carl has an MBA in Marketing and MS in Biochemistry from the University of Kansas where he conducted neurochemical research.
David Pereira, Ph.D., Senior Vice President
Dr. David Pereira has over 20 years of experience in the pharmaceutical and biotechnology industries. Prior to joining Cempra, he was a Director in the Synthesis Group of Cardinal Healthcare, where he was responsible for the process development of numerous drug candidates. He previously held positions at Baxter Healthcare in their IV Systems Division, Hemoglobin Therapeutics Group and the Corporate Research and Technical Division. He worked in parenteral drug development, medical product development and hemoglobin-based oxygen carrying solutions. Dr. Pereira earned his B.S. degree in Biochemistry from Virginia Tech followed by a Ph.D. in Medicinal Chemistry from Virginia Commonwealth University. He continued his training as a post-doctoral fellow at the University of Illinois.
David Oldach, M.D., FIDSA, Senior Vice President of Clinical Research
David Oldach joined Cempra Pharmaceuticals in 2011. Between 2006 and 2011, Dr. Oldach directed clinical research at Gilead Sciences, Inc., where his drug development experience ranged from IND/first-in-human trial development and execution through NDA-supportive Phase 3 protocol development and execution. Dr. Oldach received his Medical Degree, Magna Cum Laude, from the University of Maryland School of Medicine and completed a residency in Internal Medicine at the Massachusetts General Hospital. He completed an Infectious Disease Fellowship at Johns Hopkins University School of Medicine, serving under John Bartlett. His academic clinical research included studies in community-acquired pneumonia and surgical infections, as well as HCV pathogenesis. At the time of his transition from academic medicine to industry, Dr. Oldach was a tenured Associate Professor of Medicine at the University of Maryland School of Medicine and served as the Infectious Diseases Section Chief in the Baltimore Veterans Administration Hospital.
Gary Horwith, M.D., EVP of Regulatory Affairs
Dr. Horwith oversees regulatory chemistry, manufacturing and controls (CMC) and clinical strategies. He has 30 years of experience in clinical research and regulatory affairs and has brought numerous NCEs, vaccines, and other biological products to the IND stage, conducted Phase 1-to-3 trials and filed several NDAs during his 11 years at Wyeth and 19 years at other biotechnology and biopharmaceutical companies. Dr. Horwith received his M.D. from Autonomous University of Guadalajara, completed a residency in Internal Medicine at the University of Connecticut, an Infectious Disease Fellowship at University of California Irvine, and was a principal investigator at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) before entering the pharmaceutical industry.